|
3.5 Prévention - UV
|
|
|
|
U.S. sunscreens may not meet European standards [Reuters]
|
|
|
|
|
|
Wang
and colleagues studied 20 best-selling U.S. sunscreen products ranging
from 15 to 100 SPF and marketed as broad-spectrum. They tested the
products based on the critical wavelength requirement in the U.S. and
the UVA protection factor test in Europe.
|
|
|
|
|
|
|
3.8 Prévention - Alimentation
|
|
|
|
5. Traitements
|
|
|
|
|
Last Month in Oncology with Dr. Bishal Gyawali: February 2017
|
|
|
|
|
|
Trastuzumab
is a classic example of precision medicine by targeting HER2. But these
data tell me that while some patients definitely benefit from adjuvant
trastuzumab, many don’t. The problem is that we are drugging all
patients because we don’t know which minority will benefit. Where’s
precision in all this?
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
Study Shows Platelets Can Deliver Immunotherapy, Reduce Tumor Regrowth [NCI]
|
|
|
|
|
|
Using
mouse models of melanoma and breast cancer from which the majority of
the tumor had been surgically removed, they found that mice treated with
the engineered platelets had reduced tumor regrowth and metastasis and
lived longer than mice treated with normal platelets or the checkpoint
inhibitor alone.
|
|
|
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
OncoSec Medical and the Quest to Turn Cold Tumors Hot [The Street]
|
|
|
|
|
|
How
to turn "cold" tumors into "hot" tumors? OncoSec's approach is to
inject "cold" melanoma lesions with DNA-based interleukin-12 (IL-12), a
protein that activates components of the immune system. OncoSec then
uses a short series of electric shocks (delivered with needles) to open
the membrane of the tumor cells and help the IL-12 to enter.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
Karyopharm AML drug fails phase 2, giving stock whiplash [FierceBiotech]
|
|
|
|
|
|
Karyopharm
enrolled 176 patients with relapsed of refractory AML aged 60 years and
older and gave them either its oral inhibitor of the nuclear export
protein XPO1 or one of four physician's choice therapies, including
regimens incorporating Celgene’s Vidaza and Otsuka’s Dacogen. The trial
set out to show whether selinexor improved overall survival—and on that
front the study fell short.
|
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.6 Publications
|
|
|
|
6.9 Controverses
|
|
|